Table 2. Results of cost-effectiveness analysis by region*.
| Incremental Change | Cost-effectiveness Ratios | |||||
|---|---|---|---|---|---|---|
| Region | HCW Cases Averted | HCW Deaths Averted | Investment | Cost per Case Averted | Cost Per Death Averted | Economic Gains |
| (in millions) | (in millions) | (in millions) | ||||
| East Asia & Pacific | 51.9 (49.3 to 54.5) | 713,277 (677,963 to 748,590) | $3,711 (3,526 to 3,895) | $72 (67 to 78) | $5,237 (4,862 to 5,611) | $257,421 (247,433 to 267,407) |
| Europe & Central Asia | 9.61 (9.11 to 10.1) | 132,632 (125,831 to 139,433) | $993.4 (946.2 to 1,040) | $104 (97 to 111) | $7,541 (7,014 to 8,069) | $51,769 (49,839 to 53,698) |
| Latin America & Caribbean | 14.5 (13.7 to 15.2) | 200,069 (189,920 to 210,219) | $959.9 (914.6 to 1,005) | $67 (62 to 71) | $4,830 (4,496 to 5,164) | $72,125 (69,623 to74,986) |
| Middle East & North Africa | 9.72 (9.25 to 10.2) | 133,895 (127,364 to 140,427) | $544.7 (518.7 to 570.6) | $56 (53 to 60) | $4,094 (3,811 to 4,376) | $46,024 (44,187 to 47,865) |
| South Asia | 46.4 (44.1 to 48.7) | 640,080 (608,652 to 671,507) | $2,158 (2,056 to 2,260) | $47 (44 to 50) | $3,393 (3,163 to 3,623) | $200,343 (191,551 to 209,135) |
| Sub-Saharan Africa | 29.8 (28.4 to 31.3) | 412,148 (392,387 to 431,909) | $1,202 (1,144 to 1,259) | $41 (38 to 43) | $2,934 (2,735 to 3,132) | $123,442 (117,922 to 128,961) |
| LMIC aggregated | 161.8 (153.9 to 169.8) | 2,232,260 (2,122,083 to 2,342,436) | $9,557 (9,100 to 10,014) | $59 (55 to 63) | $4,309 (4,010 to 4,608) | $755,314 (724,335 to 786,293) |
95% confidence intervals are derived using the standard error of the simulation results.
*All monetary values are in 2020 US dollars, rounded to nearest dollar.